Cover Image
Market Research Report
Product code 
1074119

Global Cerebral Palsy Treatment Market - 2022-2029

Published: | DataM Intelligence | 180 Pages | Delivery time: 2 business days

Price

Back to Top
Global Cerebral Palsy Treatment Market - 2022-2029
Published: May 7, 2022
DataM Intelligence
Content info: 180 Pages
Delivery time: 2 business days
  • Description
  • Table of Contents

Market Overview

The global cerebral palsy treatment market size was valued US$ XX million in 2020 and is estimated to reach US$ XX million by 2028, growing at a CAGR of XX% during the forecast period (2022-2029).

Cerebral Palsy (CP), often known as "cerebral diplegia," is a collection of non-progressive, chronic illnesses marked by stiffness and mobility disability. It arises when the brain does not develop normally in the womb or due to a post-natal injury. Cerebral Palsy can affect motor function in all four limbs, resulting in balance issues, muscular contracture, coordination issues, and other neurological symptoms such as trouble managing stress levels, among other things. Although there is no cure for this ailment, therapies can help you manage it better.Surgical therapy, medicine, nutrition therapy, and other therapies such as psychiatric therapies are therapeutic choices. Corpus callosotomy, hemispherectomy, and laminectomy are some of the neurosurgical techniques used to treat epilepsy. Anticonvulsants such as phenytoin, carbamazepine, and valproic acid are among the medications used.

Market Dynamics

Cerebral palsy diagnosis entails developmental monitoring, which involves tracking the patient's development over time, and developmental screening, which entails administering a short test to determine whether the patient has any developmental delays, such as movement or motor skill delays. If the doctor discovers any discrepancies, referrals for further evaluations are made. Intervention services, such as specialized government-NGO collaboration plans, are also part of the treatment process. Increased incidences of cerebral palsy and related chronic diseases, combined with growing awareness of advanced therapeutics for rapid treatment, are expected to drive cerebral palsy treatment market growth in the coming years.

The increase in prevalance of premature births will drive the market growth

A rise in cerebral palsy cases can be attributed to various factors, including premature birth or low birth weight, multiple childbirths, and the occurrence of infectious diseases during pregnancy. Every year, an estimated 15 million babies are born prematurely. More than one out of every ten babies falls under this category. Each year, around 1 million children die due to preterm delivery problems. Many survivors may live with difficulties for the rest of their lives, including learning challenges and vision and hearing issues.

Furthermore, the mother's health conditions, such as thyroid disease, seizures, intellectual disability, and so on, can cause cerebral palsy in the child. The rapid growth of the cerebral palsy treatment market can be attributed to an increase in the incidence of cerebral palsy and an increase in parental awareness of cerebral palsy complications, and the availability of various treatment options in the market. According to the Center for Disease Control and Prevention, 1.5 to 4 out of every 1000 children in the United States have cerebral palsy. The disorder is caused primarily by abnormal development or damage to the parts of the brain that control movement, posture, and balance. Cerebral palsy is most commonly seen before birth; however, complications can occur during childbirth or shortly after birth. Methylmercury exposure during pregnancy, preterm birth, infections during pregnancy - rubella, German measles, toxoplasmosis, and herpes simplex - difficulties in delivery, asphyxia neonatorum, and intracranial hemorrhage are all risk factors for this condition.

Increased healthcare spending from both government and private-sector sources, as well as a rising trend toward new age technologically integrated healthcare processes, are likely to propel the market for cerebral palsy treatment drugs forward. This trend is more likely to be seen in regions where purchasing power parity increases. The market for cerebral palsy therapy is expected to grow even faster as the need for additional research and development investments in the pharmaceutical industry grows. This contributes to the growth of the global cerebral palsy treatment market.

Acute side effects because of the medications are likely to hamper the market growth.

Acute side effects like constipation, urinary retention, dry mouth, blurred vision associated with the administration of cerebral palsy medicines may hamper the market growth. These symptoms are expected to negatively influence the cerebral palsy treatment market as these medicines have negative effects that may cause them to be used less frequently. Furthermore, market penetration of cerebral palsy treatment surgeries is hampered by the development of non-surgical treatments such as physiotherapy and rehabilitation clinics and a shift away from surgical procedures in industrialized countries.

COVID-19 Impact Analysis

The COVID-19 outbreak is expected to harm the growth of the global cerebral palsy treatment market. The COVID-19 pandemic has put a strain on the world's healthcare system and increased the urgency of identifying the new coronavirus strain. Patients' ongoing treatments were disrupted during the lockdown. Although individuals with disabilities who live in the community were given special permission to go out, physical therapy and rehabilitation services were disrupted. Patients with cerebral palsy had to rely on telemedicine during the lockdown because they couldn't visit hospitals.

Segment Analysis

The anticonvulsants segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

Medication is a type of cerebral palsy treatment that entails taking drugs. The medicine aims to alleviate spasticity and enhance motor function, posture, and gait in such people (motor control). Anticonvulsants, such as phenobarbital and valproate semisodium, benzodiazepines, with chlordiazepoxide being the most usually administered as an adjunct therapy, and skeletal muscle relaxants as baclofen, which affects the GABA neurotransmitter system, are among the drugs used. The anticonvulsants category presently dominates the global cerebral palsy treatment market. This trend is likely to continue during the forecast period, owing to the rising cerebral palsy prevalence and an increase in anticonvulsant drug approvals by the US Food and Drug Administration (FDA).For instance,In November 2019,the FDA has approved Cenobamate tablets (marketed as Xcopri) to treat partial-onset seizures in adults. The medication was approved after two trials involving nearly 700 adults who had an average of 8.5 seizures per 28 days at the start.

Geographical Analysis

North America region holds the largest market share of global cerebral palsy treatment market

Due to increased investment in R&D, increased public awareness about mental health, favorable regulations and reimbursement policies implemented by governmental bodies, and growing health care expenditure in the region, North America is expected to account for a significant share of the global cerebral palsy treatment market.

Soon, Europe, followed by the Asia Pacific, is expected to be very profitable markets for cerebral palsy therapy. The Asia Pacific cerebral palsy treatment market is expected to rise substantially during the projected period. Soon, the market in the region is projected to be driven by a rising population and increased investment from both the public and private sectors. Furthermore, expanding technological penetration, combined with rising public knowledge about the consequences and treatment of cerebral palsy, is expected to drive the growth of the cerebral palsy treatment market. Due to the implementation of favorable government regulations and an increase in health care expenditure by both public and private organizations, the cerebral palsy treatment market in the Middle East & Africa and Latin America is expected to develop significantly during the projected period.

Competitive Landscape

The cerebral palsy treatment market is fiercely competitive, with several main players. Few big firms currently dominate the market in terms of market share. Several companies have been identified to be investing in their R&D to develop unique and sophisticated therapeutic medications for cerebral illnesses. As a result, shortly, the industry will be driven by research and development of highly effective pharmaceutical medications with few or no adverse effects. The companies also use organic growth techniques such as new releases, product approvals, and others such as patents and events. Some of the key players which are contributing to the growth of the market include Allergen Plc, Dr. Reddy Laboratories, Sun Pharmaceuticals Industries Ltd, Viatris , Scortis Pharma Ltd, Lupin Pharmaceutical ,GlaxoSmithKline , Janssen Pharmaceuticals Inc, Pfizer. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the cerebral palsy treatment market globally. For instance October 2019, BOTOX® (onabotulinumtoxinA) had been approved by the FDA for pediatric patients with lower limb spasticity, excluding spasticity caused by Cerebral Palsy.

Lupin Pharmaceuticals

Overview: Lupin Limited, situated in Mumbai, Maharashtra, India, is an Indian multinational pharmaceutical corporation. It is one of the world's most profitable generic pharmaceutical companies. Pediatrics, cardiovascular, anti-infectives, diabetology, asthma, and anti-tuberculosis are among the company's primary emphasis areas.

Product Portfolio:

Escitalopram: Escitalopram is used to treat depression and anxiety. It works by assisting in restoring the balance of a natural substance (serotonin) in the brain. Escitalopram is a drug in a class known as selective serotonin reuptake inhibitors (SSRI). It may increase your energy and well-being while decreasing nervousness.

Why Purchase the Report?

Visualize the composition of the global cerebral palsy treatment market segmentation by treatment, Disease Type, Diagnosis, end user and region highlighting the key commercial assets and players.

Identify commercial opportunities in global cerebral palsy treatment market by analyzing trends and co-development deals.

Excel data sheet with thousands of data points of global cerebral palsy treatment market- level 4/5 segmentation.

PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

Product mapping in excel for the key product of all major market players

The global cerebral palsy treatment market report would provide an access to an approximately 40+ market data table, 45+ figures and 180 pages.

Target Audience

Service Providers/ Buyers

Industry Investors/Investment Bankers

Education & Research Institutes

Research Professionals

Emerging Companies

Manufacturers

Product Code: DMPH4902

Table of Contents

1. Global Cerebral Palsy Treatment Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Global Cerebral Palsy Treatment Market- Market Definition and Overview

3. Global Cerebral Palsy Treatment Market- Executive Summary

  • 3.1. Market Snippet by Drug Type
  • 3.2. Market snippet by Disease Type
  • 3.3. Market snippet by End User
  • 3.4. Market Snippet by Region

4. Global Cerebral Palsy Treatment Market- Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Growing prevalence of cerebral palsy coupled with increasing awareness about the condition.
      • 4.1.1.2. Increasing government funding for healthcare.
      • 4.1.1.3. Rise in premature births.
    • 4.1.2. Restraints:
      • 4.1.2.1. High treatment cost.
      • 4.1.2.2. Lack of awareness about the disease.
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Global Cerebral Palsy Treatment Market- Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Reimbursement Analysis

6. Global Cerebral Palsy Treatment Market- COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. Global Cerebral Palsy Treatment Market- By Drug Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type Segment
    • 7.1.2. Market Attractiveness Index, By Drug Type Segment
  • 7.2. Anticonvulsants*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 7.3. Antidepressants
  • 7.4. Anti-inflammatories
  • 7.5. Muscle relaxants
  • 7.6. Benzodiazepines
  • 7.7. Nerve blocks
  • 7.8. Botox
  • 7.9. Baclofen
  • 7.10. Anticholinergics
  • 7.11. Stool Softeners

8. Global Cerebral Palsy Treatment Market- By Disease Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%),By Disease Type
    • 8.1.2. Market Attractiveness Index, By Disease Type
  • 8.2. Spastic Cerebral Palsy Treatment*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 8.3. Dyskinetic Cerebral Palsy Treatment
  • 8.4. Ataxic Cerebral Palsy Treatment
  • 8.5. Mixed Cerebral Palsy Treatment

9. Global Cerebral Palsy Treatment Market- By Distribution Channel

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.1.2. Market Attractiveness Index, By Distribution Channel Segment
  • 9.2. Hospital Pharmacies*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 9.3. Retail Stores & Pharmacy
  • 9.4. Online Providers
  • 9.5. Others

10. Global Cerebral Palsy Treatment Market- By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 10.2.5. Market Size Analysis ,and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%),By Distribution Channel
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.3.7.
      • 10.3.7.1. Germany
      • 10.3.7.2. U.K.
      • 10.3.7.3. France
      • 10.3.7.4. Italy
      • 10.3.7.5. Spain
      • 10.3.7.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%),By Disease Type
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Global Cerebral Palsy Treatment Market- Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Product Benchmarking
  • 11.4. Key Companies to Watch

12. Global Cerebral Palsy Treatment Market- Company Profiles

  • 12.1. Lupin Pharmaceuticals*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Allergen
  • 12.3. Dr.Reddy Laboratories
  • 12.4. Sun Pharmaceuticals Industries Ltd
  • 12.5. Viatris
  • 12.6. Scortis Pharmaceuticals Ltd
  • 12.7. GlaxoSmithKline
  • 12.8. Janssen Pharmaceuticals Inc
  • 12.9. Pfizer

LIST NOT EXHAUSTIVE

13. Global Cerebral Palsy Treatment Market- DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us